For generations, a drug capable of easing the suffering of children born with sickle cell anemia was withheld from those who needed it most — not for lack of evidence that it worked, but for fear that it might harm them in ways that could not be quickly corrected in places far from hospitals. A decade-long trial across four African nations has now answered that fear with data: hydroxyurea, given at the highest tolerable dose, does not increase infection risk in children living in low-resource settings — it reduces it. The finding redraws the boundary between caution and neglect, and invites a
Decade-long trial confirms hydroxyurea safely treats sickle cell in Africa
Approximately 550,000 children born annually with sickle cell anemia experience pain, infection vulnerability, and chronic illness; this treatment offers significant relief.
No increase in illness or death from infections, even at maximum dose.
Mark
Why did doctors hesitate to use hydroxyurea in Africa if it was already proven safe in wealthy countries?
Mimi
Because the drug suppresses neutrophils—infection-fighting white blood cells. In places with limited hospital access and endemic malaria, that seemed like a dangerous trade-off. The theory was sound: suppress immunity, increase infection risk. But it had never been tested at scale in those settings.
Luke
So this trial was essentially testing a hypothesis that turned out to be wrong?
Mimi
Not wrong exactly—just incomplete. The drug does suppress neutrophils. But the study found that didn't translate into more infections in practice. In fact, infection rates dropped.
Mark
How is that possible? If the immune system is suppressed, shouldn't infections increase?
Mimi
That's the puzzle the trial solved. Over 5,000 patient-years of follow-up, malaria infections fell 51 percent and other infections fell 38 percent. The researchers don't fully explain the mechanism, but the data is clear.
Luke
Wait—were they actively testing for infections in real time, or relying on what patients reported?
Mimi
Mostly the latter. Most infections were reported retrospectively through clinical history rather than real-time testing. That's a limitation worth noting.
Mark
Does that weaken the findings?
Luke
It means we're relying on what patients and families remembered and reported. In a low-resource setting, some infections might be missed or underreported. But the direction of the finding—fewer infections, not more—is still striking.
Mark
So what happens now?
Mimi
The researchers recommend hydroxyurea become standard care for sickle cell patients in low-income settings. About 80 percent of sickle cell cases globally occur in sub-Saharan Africa, so this could affect hundreds of thousands of children.
Mark
Is there any reason doctors might still hold back?
Luke
Access and cost. The trial proves safety, but getting the drug to remote areas, monitoring patients regularly, managing dosing—that's infrastructure. The science is settled. The implementation is the next question.
Der Puls
- Roughly 550,000 children are born with sickle cell anemia each year, and 80% of them live in sub-Saharan Africa — the very places where the most effective treatment has been withheld.
- Doctors feared that hydroxyurea's immune-suppressing effects would leave children in malaria-endemic, resource-scarce regions dangerously exposed to fatal infections.
- The REACH trial followed 606 children across Angola, DRC, Kenya, and Uganda for over a decade, systematically testing whether that fear had any basis in reality.
- Instead of more infections, researchers found fewer — malaria rates fell by 51% and other infections by 38%, with no increase in serious or life-threatening illness even at maximum doses.
- Published in The Lancet Haematology, the findings now support making hydroxyurea standard care in low-income settings, closing a gap that caution — not evidence — had created.
For generations, a drug capable of easing the suffering of children born with sickle cell anemia was withheld from those who needed it most — not for lack of evidence that it worked, but for fear that it might harm them in ways that could not be quickly corrected in places far from hospitals. A decade-long trial across four African nations has now answered that fear with data: hydroxyurea, given at the highest tolerable dose, does not increase infection risk in children living in low-resource settings — it reduces it. The finding redraws the boundary between caution and neglect, and invites a reckoning with how long theoretical risk was allowed to stand in for actual evidence.
A decade-long clinical trial has answered one of the most consequential questions in global pediatric medicine: whether a drug that relieves sickle cell anemia might also leave children in low-resource settings dangerously vulnerable to infection. After more than 5,000 patient-years of follow-up across Angola, the Democratic Republic of the Congo, Kenya, and Uganda, the answer is no.
Hydroxyurea works by prompting the body to produce fetal hemoglobin, which prevents red blood cells from contorting into the sickle shape that defines the disease. Taken once daily, it has been standard care in wealthy countries for years. But in low-income settings, physicians hesitated. The drug suppresses neutrophils — the white blood cells that fight infection — and in places where malaria is endemic and hospitals are distant, that trade-off seemed too dangerous to accept without proof.
The REACH trial was built to test that assumption. Researchers enrolled 606 children between ages one and ten, starting them on a fixed dose before escalating to the maximum each child could tolerate. What they found overturned the prevailing caution: children on higher doses did not experience more infections — they experienced significantly fewer. Malaria fell by 51 percent. Other bacterial and viral infections dropped by 38 percent. Serious or life-threatening infections did not increase, even at maximum doses.
Sickle cell anemia is the world's most common severe inherited blood disorder, and roughly 80 percent of its 550,000 annual cases are born in sub-Saharan Africa. For these children, the disease means chronic pain, infection vulnerability, and shortened lives. Lead researcher Tom Williams of Imperial College London noted that the study's scale — more than a decade of follow-up — provides the kind of reassurance that had simply never existed before. Senior author Russell Ware of Cincinnati Children's Hospital called the findings long-awaited confirmation that maximum-dose hydroxyurea is safe over the long term.
The researchers now recommend hydroxyurea at maximum tolerated doses as standard care in low-resource settings. For hundreds of thousands of children born each year in the places where sickle cell is most prevalent, a door that caution had kept closed is now open.
A decade-long clinical trial has settled a question that has haunted doctors treating sickle cell anemia in Africa: whether a drug that could save lives might also make patients more vulnerable to deadly infections. The answer, after following 606 children across four countries for more than ten years, is no.
Hydroxyurea works by coaxing the body to produce more fetal hemoglobin—the form of hemoglobin that babies make in the womb and that prevents red blood cells from taking on the characteristic sickle shape that gives the disease its name. Taken once daily by mouth, it has been standard treatment in wealthy countries for years. But in low-income settings, doctors have held back. The drug suppresses neutrophils, the white blood cells that fight infection. In places where a child cannot easily reach a hospital, where malaria is endemic, where bacterial infections can turn fatal without antibiotics, that trade-off seemed too risky to make.
The REACH trial—Realizing Effectiveness Across Continents with Hydroxyurea—was designed to test whether that caution was justified. Researchers enrolled children ages one to ten between 2014 and 2016 at sites in Angola, the Democratic Republic of the Congo, Kenya, and Uganda. They started patients on a fixed dose of hydroxyurea for six months, then increased it to the maximum each child could tolerate. Every two to three months, they checked in. Over more than 5,000 patient-years of follow-up, they tracked infections.
What they found was unexpected enough to reshape treatment guidelines. Children on higher doses of hydroxyurea did not get more infections. They got fewer. Malaria infections dropped by 51 percent. Other bacterial and viral infections fell by 38 percent. There was no increase in serious or life-threatening infections, even at maximum tolerated doses. The incidence and severity of infections, in many cases, actually declined.
Sickle cell anemia is the most common severe inherited blood disorder in the world. About 550,000 children are born with it each year, and roughly 80 percent of those cases occur in sub-Saharan Africa. The disease brings chronic pain, vulnerability to infections, and a shortened lifespan. Bacterial and viral infections—including malaria—are among its most dangerous complications. For decades, hydroxyurea has offered relief in high-income countries. But for the vast majority of children living with sickle cell, in places with limited medical resources, the drug remained out of reach, held back by a theoretical risk that had never been properly tested.
The study, published in The Lancet Haematology, was led by Tom Williams, a professor at Imperial College London's Institute of Global Health Innovation. "Many doctors are cautious about using hydroxyurea because they are worried that it will increase the risks of severe or fatal infections," Williams said. "In this huge study covering more than 5,000 patient-years of follow-up, we found no increase in illness or death from infections, even when hydroxyurea is used at the maximum tolerated dose."
Russell Ware, a senior author and professor at Cincinnati Children's Hospital Medical Center, framed the findings as long-awaited confirmation. "These findings provide long-awaited data regarding the long-term safety of hydroxyurea used at the maximum tolerated dose in low-income settings. Over 10 years of treatment, the incidence and severity of infections did not increase and, in many cases, decreased."
The researchers now recommend that children with sickle cell anemia in low-resource settings receive hydroxyurea at the maximum tolerated dose. Williams added that the results "provide strong reassurance that the incidence and severity of infections are not increased with long-term or maximum-dose hydroxyurea treatment. These findings support the wider use of hydroxyurea as standard care." For hundreds of thousands of children born each year into places where the disease is most common, the trial's conclusion opens a door that caution had kept closed.
Bemerkenswerte Zitate
In this huge study covering more than 5,000 patient-years of follow-up, we found no increase in illness or death from infections, even when hydroxyurea is used at the maximum tolerated dose.— Tom Williams, Imperial College London Institute of Global Health Innovation
These findings support the wider use of hydroxyurea as standard care.— Tom Williams
Möchten Sie die ganze Geschichte?
Das Original lesen bei Medical Xpress ↗
Health & Medicine